Treatment Efficacy Clinical Trial
Official title:
Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock
The aim of study is this to evaluate the efficacy and safety of continuous linezolid infusion versus the standard regimen in treating critically ill patients with septic shock in the ICU
Status | Recruiting |
Enrollment | 140 |
Est. completion date | December 2, 2023 |
Est. primary completion date | December 2, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - adult patients aged > 18 years old - diagnosis of septic shock (patient with septic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial blood pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol\L (>18 mg\dL) in the absence of hypovolemia). - positive culture confirming linezolid susceptibility. Exclusion Criteria: - Patient refusal. - Known allergy to linezolid. - Pregnancy and lactation. - Severe hepatic failure (Child-Pugh C). - Thrombocytopenia (platelet count < 80,000/mm3). - Disseminated intravascular coagulation (DIC). - Hematologic disease, and concurrent use of other medications that may interact with linezolid (i.e., macrolides, serotonin modulators), or drug-associated thrombocytopenia. |
Country | Name | City | State |
---|---|---|---|
Egypt | Ain Shams University | Cairo |
Lead Sponsor | Collaborator |
---|---|
Ain Shams University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | occurrence of medical cure | primary outcome defined as occurrence of medical cure on day 7 following linezolid initiation. Clinical cure will be indicated as normal body temperature(36.1 C- 37.2C). | 7 days | |
Secondary | secondary outcomes | ICU stay(days)
duration of hospital stay (days). duration of linezolid treatment until clinical cure(days). Mortality at the end of treatment, and 30-day mortality. |
30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04508803 -
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT05087381 -
Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community
|
Phase 4 | |
Active, not recruiting |
NCT02551523 -
Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection
|
Phase 2 | |
Recruiting |
NCT06221722 -
Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation
|
||
Terminated |
NCT03503968 -
TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06460883 -
Effects of Eccentric Banded Leg Curls Versus Eccentric Cable Leg Curls Exercises in Cricket Players
|
N/A | |
Completed |
NCT02572947 -
A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients
|
Phase 2 | |
Completed |
NCT05144295 -
Lubiprostone for Functional Constipation in the Under 18 Years Patients
|
Phase 3 | |
Completed |
NCT03345160 -
Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study
|
Phase 2 |